LNSR Quote, Financials, Valuation and Earnings

Henry Schein has a net margin of -111.78% compared to LENSAR's net margin of 2.95%. LENSAR's return on equity of -134.77% beat Henry Schein's return on equity of 7.8%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 11.19%. On the other hand Henry Schein has an analysts' consensus of $77.85 which suggests that it could grow by 20.77%. Given that Henry Schein has higher upside potential than LENSAR, analysts believe Henry Schein is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Henry Schein has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.587%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Henry Schein offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Henry Schein pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $16.7M, which are smaller than Henry Schein quarterly revenues of $3.2B. LENSAR's net income of -$18.7M is lower than Henry Schein's net income of $94M. Notably, LENSAR's price-to-earnings ratio is -- while Henry Schein's PE ratio is 21.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.90x versus 0.65x for Henry Schein. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -111.78% compared to LENSAR's net margin of -72.93%. LENSAR's return on equity of -134.77% beat Standard BioTools's return on equity of -36.54%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 11.19%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 106.52%. Given that Standard BioTools has higher upside potential than LENSAR, analysts believe Standard BioTools is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.541, suggesting its more volatile than the S&P 500 by 54.101%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $16.7M, which are smaller than Standard BioTools quarterly revenues of $46.7M. LENSAR's net income of -$18.7M is higher than Standard BioTools's net income of -$34.1M. Notably, LENSAR's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.90x versus 2.33x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

NeuroPace has a net margin of -111.78% compared to LENSAR's net margin of -24.46%. LENSAR's return on equity of -134.77% beat NeuroPace's return on equity of -216.38%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 11.19%. On the other hand NeuroPace has an analysts' consensus of $16.86 which suggests that it could grow by 61.78%. Given that NeuroPace has higher upside potential than LENSAR, analysts believe NeuroPace is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NeuroPace has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. NeuroPace pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $16.7M, which are smaller than NeuroPace quarterly revenues of $21.5M. LENSAR's net income of -$18.7M is lower than NeuroPace's net income of -$5.3M. Notably, LENSAR's price-to-earnings ratio is -- while NeuroPace's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.90x versus 3.80x for NeuroPace. Usually stocks with elevated PS ratios are considered overvalued.

Patterson Companies has a net margin of -111.78% compared to LENSAR's net margin of 1.99%. LENSAR's return on equity of -134.77% beat Patterson Companies's return on equity of 14.22%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 11.19%. On the other hand Patterson Companies has an analysts' consensus of $30.42 which suggests that it could fall by -1.6%. Given that LENSAR has higher upside potential than Patterson Companies, analysts believe LENSAR is more attractive than Patterson Companies.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Patterson Companies has a beta of 0.731, suggesting its less volatile than the S&P 500 by 26.948%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Patterson Companies offers a yield of 3.37% to investors and pays a quarterly dividend of $0.26 per share. LENSAR pays -- of its earnings as a dividend. Patterson Companies pays out 52.89% of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LENSAR quarterly revenues are $16.7M, which are smaller than Patterson Companies quarterly revenues of $1.6B. LENSAR's net income of -$18.7M is lower than Patterson Companies's net income of $31.3M. Notably, LENSAR's price-to-earnings ratio is -- while Patterson Companies's PE ratio is 20.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 2.90x versus 0.42x for Patterson Companies. Usually stocks with elevated PS ratios are considered overvalued.